Toft-Nielsen MB - Search Results

1

Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.

Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ. Vilsbøll T, et al. Among authors: toft nielsen mb. Diabetes Care. 2000 Jun;23(6):807-12. doi: 10.2337/diacare.23.6.807. Diabetes Care. 2000. PMID: 10841001

2

On the treatment of diabetes mellitus with glucagon-like peptide-1.

Holst JJ, Deacon C, Toft-Nielsen MB, Bjerre-Knudsen L. Holst JJ, et al. Among authors: toft nielsen mb. Ann N Y Acad Sci. 1998 Dec 11;865:336-43. doi: 10.1111/j.1749-6632.1998.tb11193.x. Ann N Y Acad Sci. 1998. PMID: 9928027 Review.

3

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen MB, Madsbad S, Holst JJ. Toft-Nielsen MB, et al. Diabetes Care. 1999 Jul;22(7):1137-43. doi: 10.2337/diacare.22.7.1137. Diabetes Care. 1999. PMID: 10388979 Clinical Trial.

4

Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.

Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S, Holst JJ. Zander M, et al. Among authors: toft nielsen mb. Diabetes Care. 2001 Apr;24(4):720-5. doi: 10.2337/diacare.24.4.720. Diabetes Care. 2001. PMID: 11315837 Clinical Trial.

5

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.

Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ. Toft-Nielsen MB, et al. J Clin Endocrinol Metab. 2001 Aug;86(8):3717-23. doi: 10.1210/jcem.86.8.7750. J Clin Endocrinol Metab. 2001. PMID: 11502801

6

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.

Toft-Nielsen MB, Madsbad S, Holst JJ. Toft-Nielsen MB, et al. J Clin Endocrinol Metab. 2001 Aug;86(8):3853-60. doi: 10.1210/jcem.86.8.7743. J Clin Endocrinol Metab. 2001. PMID: 11502823

7

Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects.

Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Deacon CF, et al. Diabetes. 1995 Sep;44(9):1126-31. doi: 10.2337/diab.44.9.1126. Diabetes. 1995. PMID: 7657039

8

No effect of beta-adrenergic blockade on hypoglycaemic effect of glucagon-like peptide-1 (GLP-1) in normal subjects.

Toft-Nielsen M, Hvidberg A, Hilsted J, Dige-Petersen H, Holst JJ. Toft-Nielsen M, et al. Diabet Med. 1996 Jun;13(6):544-8. doi: 10.1002/(SICI)1096-9136(199606)13:6<544::AID-DIA129>3.0.CO;2-X. Diabet Med. 1996. PMID: 8799658 Clinical Trial.

9

Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia.

Toft-Nielsen M, Madsbad S, Holst JJ. Toft-Nielsen M, et al. Diabetologia. 1998 Oct;41(10):1180-6. doi: 10.1007/s001250051049. Diabetologia. 1998. PMID: 9794105

10

On the effects of glucagon-like peptide-1 on blood glucose regulation in normal and diabetic subjects.

Holst JJ, Toft-Nielsen MB, Orskov C, Nauck M, Willms B. Holst JJ, et al. Among authors: toft nielsen mb. Ann N Y Acad Sci. 1996 Dec 26;805:729-36. doi: 10.1111/j.1749-6632.1996.tb17549.x. Ann N Y Acad Sci. 1996. PMID: 8993469 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters